Testing a new drug for lymphoma with MYC gene changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests the safety of a new drug, CX-5461 (Pidnarulex), in people with certain types of aggressive B-cell lymphoma that have specific MYC gene changes. It aims to find out if this drug can help when standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called double-expressor lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 changes, or Burkitt lymphoma.
- You have tried at least two prior treatments for diffuse large B-cell lymphoma, or at least one prior treatment for Burkitt lymphoma, and no standard treatments are effective.
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status 2 or less).
- Your blood counts and liver and kidney function are within certain limits.
- You agree to use effective contraception during and for 6 months after the study, if applicable.
- You are willing to provide blood and tissue samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This Phase 2 study tests a treatment sequence for people with high-risk diffuse large B-cell lymphoma (DLBCL) that includes loncastuximab plus rituximab, then DA-EPOCH-R. It aims to improve responses in patients whose lymphoma has specific high-risk features.
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests whether a new combination of chemotherapy drugs (P-GEMD) works better than the standard combination (P-Gemox) for people with certain types of natural killer/T-cell lymphoma (a rare blood cancer). It's designed for newly diagnosed or advanced-stage patients who haven't been treated yet.
Hear when a new Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.